CLASS II Device recall · Reported 16 Sep 2020 · FDA Enforcement Report

QIAstat-Dx Respiratory Sars-CoV-2 Panel recalled by Qiagen Sciences

Qiagen Sciences is recalling QIAstat-Dx Respiratory Sars-CoV-2 Panel, distributed nationwide in the US. The recall was initiated on 15 Jul 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codeslots 166020729, 166022794, 166023368, 166023399, 166023400, 166024163, 166024165, 166024166, 166025078, 166025888, 166025889, 166028721, 166028722, 166029506, 166029508
Quantity recalled1474 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2938-2020
FDA event ID
86149
Recalling firm
Qiagen Sciences, Germantown, MD
Classification
Class II
Status
Terminated
Recall initiated
15 Jul 2020
FDA classified
4 Sep 2020
Reported
16 Sep 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

15 Jul 2020Recall initiated by company
4 Sep 2020Classified by FDA+51 days
16 Sep 2020Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

There is an increased rate of potential false positive results for the Influenza A (no subtype) target, which may lead to 1) inappropriate antiviral use, 2) erroneous or delayed differential diagnosis and missing of an alternative diagnosis.

Product as listed by the FDA

QIAstat-Dx Respiratory SARS-CoV-2 Panel REF 691223 (US IVD under FDA EUA) - Product Usage: intended for the qualitative detection and differentiation of nucleic acid from multiple respiratory viral and bacterial organisms, including the SARS-CoV-2 virus, in nasopharyngeal swabs (NPS) eluted in universal transport media collected from patients suspected of COVID-19 by their healthcare provider.

Where it was distributed

US Nationwide distribution including in the states of AK, AL, CA, DC, DE, FL, GA, IL, IN, KY, MA, MD, MN, NC, NJ, NY, OH, OR, PA, TX, WA.

Nationwide AlaskaAlabamaCaliforniaDistrict of ColumbiaDelawareFloridaGeorgiaIllinoisIndianaKentuckyMassachusettsMarylandMinnesotaNorth CarolinaNew JerseyNew YorkOhioOregonPennsylvaniaTexas

Questions about this recall

Why was it recalled?

There is an increased rate of potential false positive results for the Influenza A (no subtype) target, which may lead to 1) inappropriate antiviral use, 2) erroneous or delayed differential diagnosis and missing of an alternative diagnosis.

Which lots are affected?

lots 166020729, 166022794, 166023368, 166023399, 166023400, 166024163, 166024165, 166024166, 166025078, 166025888, 166025889, 166028721, 166028722, 166029506, 166029508

Where was it sold?

US Nationwide distribution including in the states of AK, AL, CA, DC, DE, FL, GA, IL, IN, KY, MA, MD, MN, NC, NJ, NY, OH, OR, PA, TX, WA.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Qiagen Sciences

All 23

Other CPAP & Ventilators recalls

All 552